This document discusses assessing the value of new antibiotics through health technology assessment (HTA). It identifies four benefits typically included in HTA evaluations and six additional benefits not traditionally considered but relevant for antibiotics. These additional benefits include insurance value, diversity value, diagnostic value, uniqueness, enablement value, and spectrum value. The document notes that HTA methods may not fully capture the value of antibiotics in addressing antimicrobial resistance and that new payment mechanisms are needed given antibiotics must have limited use to delay resistance development.